Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

doi:10.12998/wjcc.v12.i4.700

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2317)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-14) series, Tables (1-2) series.

Item

Count

PDF

119

WORD

HTML

1203

Figures (1-14)

195

Tables (1-2)

174

Sum=1716

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

123

Download

414

Sum=537

Feb 6, 2024 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Clin Cases. Feb 6, 2024; 12(4): 700-720
Published online Feb 6, 2024. doi: 10.12998/wjcc.v12.i4.700

Full Size Figure Download Figure

Figure 12 Prediction of chemotherapy response. A: The cancer associated fibroblast risk score of estimated chemotherapy-responders and non-responders in GSE18728; B: Distributions of responders and non-responders in high- and low-risk groups in GSE18728.

Citation: Wu ZZ, Wei YJ, Li T, Zheng J, Liu YF, Han M. Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer. World J Clin Cases 2024; 12(4): 700-720
URL: https://www.wjgnet.com/2307-8960/full/v12/i4/700.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i4.700